I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Diabetes prevalence in Kuwait is estimated to be 15.9%, with 298 thousand people with diabetes.\[[@ref1]\] Fear of hypoglycaemia and gain in body weight are barriers for initiation of insulin therapy.\[[@ref2]\] Modern insulin analogues are a convenient new approach or tool to glycaemic control, associated with low number of hypoglycaemia and favourable weight change.\[[@ref3]\] A~1~chieve, a multinational, 24-week, non-interventional study, assessed the safety and effectiveness of insulin analogues in people with T2DM (*n* = 66,726) in routine clinical care.\[[@ref4]\] This short communication presents the results for patients enrolled from Kuwait.

M[ATERIALS AND]{.smallcaps} M[ETHODS]{.smallcaps} {#sec1-2}
=================================================

Please refer to editorial titled: The A~1~chieve study: Mapping the Ibn Battuta trail.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

A total of 1185 patients were enrolled in the study. The patient characteristics for the entire cohort divided as insulin-naïve and insulin users is shown in the [Table 1](#T1){ref-type="table"}. Glycaemic control at baseline was poor in this population. The majority of patients started on or were switched to biphasic insulin aspart (39.8%) or insulin detemir (39.8%). Other groups were insulin aspart (*n* = 4), basal insulin plus insulin aspart (*n* = 188) and other insulin combinations (*n* = 48). After 24 weeks of treatment, overall hypoglycaemic events reduced from 8.9 events/patient-year to 3.2 events/patient-year in insulin user group whereas hypoglycaemia increased from 0.3 events/patient-year to 1.9 events/patient-year in insulin naive group. However, this hypoglycaemia incidence in insulin naive group at 24 weeks was still lower than that observed in insulin users at baseline. No major hypoglycaemic episodes were observed at 24 weeks. SADR was reported in 0.1% of insulin users. Body weight decreased and overall lipid profile improved at week 24 in complete cohort \[Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}\].
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Overall demographic data
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Overall safety data
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###### 

Insulin dose
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All parameters of glycaemic control improved from baseline to study end in the total cohort \[[Table 4](#T4){ref-type="table"}\].

###### 

Overall efficacy data
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Biphasic insulin aspart ± OGLD {#sec2-1}
------------------------------

Of the total cohort, 472 patients started on biphasic insulin aspart ± OGLD, of which 128 (27.1%) were insulin naïve and 344 (72.9%) were insulin users. After 24 weeks of starting or switching to biphasic insulin aspart, hypoglycaemic events reduced from 9.0 events/patient-year to 2.2 events/patient-year in insulin user group while hypoglycaemia increased from 0.6 events/patient-year to 2.0 events/patient-year in insulin naive group. Body weight decreased after 24 weeks in insulin user group \[Tables [5](#T5){ref-type="table"} and [6](#T6){ref-type="table"}\].

###### 

Biphasic insulin aspart±oral glucose-lowering drug safety data
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###### 

Insulin dose
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All parameters of glycaemic control improved from baseline to study end in those who started on or were switched to biphasic insulin aspart for both insulin naïve and insulin user groups \[[Table 7](#T7){ref-type="table"}\].

###### 

Biphasic insulin aspart±oral glucose-lowering drug efficacy data
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Basal + insulin aspart ± OGLD {#sec2-2}
-----------------------------

Of the total cohort, 188 patients started on basal + insulin aspart ± OGLD, of which 13 (6.9%) were insulin naïve and 175 (93.1%) were insulin users. After 24 weeks of starting or switching to basal + insulin aspart, hypoglycaemic events reduced from 10.6 events/patient-year to 6.1 events/patient-year in insulin user group whereas hypoglycaemia increased from 0.0 events/patient-year to 1.2 events/patient-year in insulin naive group. A decrease in body weight was observed in both insulin naive and insulin user groups \[Tables [8](#T8){ref-type="table"} and [9](#T9){ref-type="table"}\].

###### 

Basal+insulin aspart±oral glucose-lowering drug safety data
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###### 

Insulin dose
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All parameters of glycaemic control improved from baseline to study end in those who started on or were switched to basal + insulin aspart ± OGLDs for both insulin naïve and insulin user groups \[[Table 10](#T10){ref-type="table"}\].

###### 

Basal+insulin aspart±oral glucose-lowering drug efficacy data
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Insulin detemir ± OGLD {#sec2-3}
----------------------

Of the total cohort, 472 patients started on insulin detemir ± OGLD, of which 359 (76.1%) were insulin naïve and 113 (23.9%) were insulin users. After 24 weeks of starting or switching to insulin detemir, hypoglycaemic events reduced from 4.7 events/patient-year to 1.8 events/patient-year in insulin user group whereas hypoglycaemia increased from 0.3 events/patient-year to 1.7 events/patient-year in insulin naive group. Body weight decreased in both insulin naive and insulin user groups \[Tables [11](#T11){ref-type="table"} and [12](#T12){ref-type="table"}\].

###### 

Insulin detemir±oral glucose-lowering drug safety data

![](IJEM-17-465-g011)

###### 

Insulin dose
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All parameters of glycaemic control improved from baseline to study end in those who started on or were switched to insulin detemir ± OGLDs for both insulin-naïve and insulin user groups \[[Table 13](#T13){ref-type="table"}\].

###### 

Insulin detemir±oral glucose-lowering drug efficacy data
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Insulin aspart ± OGLD {#sec2-4}
---------------------

Of the total cohort, 4 patients started on insulin aspart ± OGLD of which 1 (25%) were insulin naïve and 3 (75%) were insulin users. After 24 weeks of treatment starting or switching to insulin aspart, hypoglycaemic events reduced from 13.0 events/patient-year to 0.0 events/patient-year in insulin user group, while hypoglycaemia remained nil in insulin naïve group similar to that of baseline. Body weight decreased in insulin user group. All parameters of glycaemic control improved from baseline to study end in those who started on or were switched to insulin aspart ± OGLDs for both insulin naïve and insulin user groups.

C[ONCLUSION]{.smallcaps} {#sec1-4}
========================

Our study reports improved glycaemic control following 24 weeks of treatment with any of the insulin analogues (Biphasic insulin aspart; basal + insulin aspart; insulin detemir; insulin aspart) with or without OGLD. No major hypoglycaemic episodes were observed at 24 weeks. SADR was reported in 0.1% of insulin users. Though the findings are limited by number of patients, still the trend indicates that insulin analogues can be considered effective and possess a safe profile for treating type 2 diabetes in Kuwait.
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